United Cannabis Corporation Release: FDA Approval Of Medical MJ: Phase I Human Studies Explored By Team Of Experts
6/4/2014 11:09:37 AM
Denver – June 4, 2014 – Recent appointees to a team of experts will explore the safety data required for Institutional Review Board (IRB) and FDA approval of human (Phase I, II, III) studies on the use of medicinal marijuana
Brent A. Reynolds PhD, and Dennis A. Steindler PhD will focus on the Federal requirements necessary for approval to market medicinal marijuana drugs in legal communities. As newly appointed Directors, Drs. Reynolds and Steindler will run and manage the Discovery Research & Development division of United Cannabis Corporation. The Doctors will establish evidence of cannabis-based medical efficacy, and create Intellectual Property (IP) on medically efficient cannabinoid-based products
Exploring the medical applications of cannabinoids, the Doctors will focus on IP claims, protecting products and their application, pre-clinical exploratory, proof of principal, and the safety data required for Institutional Review Board (IRB) and FDA approval of human (Phase I, II, III) studies on the use of medicinal marijuana.
Dr. Reynolds treats diseases and dysfunction of the nervous system. Dr. Steindler diagnoses and treats neurodegenerative diseases and cancer. Drs. Reynolds and Steindler have a record of patent protection and product development.
"Based on the evidence and efficacy of our programs, we are building a foundation established on human studies. United Cannabis will seek out the science behind full spectrum cannabinoids to develop synergistic medicine that compliments conventional therapies. The Company now has an opportunity that not only allows us to research the plant, but with the recently appointed expert team of Drs. Reynolds and Steindler, we can convert those findings into realized products FDA approved for medical applications," notes Tony Verzura, VP United Cannabis Corporation.
About United Cannabis Corporation
United Cannabis Corporation has a solid foundation in the Cannabis industry. With consulting services, management, and oversight the Company is capable of assisting many Cannabis-oriented firms on any scale. United Cannabis Corporation is now partnering domestically and internationally with local businessmen, entrepreneurs, scientists, and government agencies for the purpose of promoting Best Practices in Planning, Procedures, Governance and Patient Care. The Company consults and provides guidance on design and construction of growth facilities and cultivation of medical grade cannabis-based products worldwide. With access to a catalog of award winning genetics (200 strains including over 15 unique CBD dominant strains), and coupled with United Cannabis Corporation leadership and experience, the Company is positioned to take many Cannabis businesses through the steps necessary for success. For further information, please visit www.unitedcannabis.us
Forward looking information
UCANN believes the information set forth in this Press Release may include "forward looking information" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in "Risk Factors" in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on February 18, 2014.
Help employers find you! Check out all the jobs and post your resume.